Medivation (NASDAQ: MDVN) and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that they have entered into an asset purchase agreement under ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Mergers and Acquisitions Spinoffs

Medivation's (MDVN) Talazoparib Acquisition is 'Good Use of Cash' - Maxim (BMRN)August 26, 2015 7:25 AM UBS Raises Price Target on Medivation (MDVN) Following Talazoparib Acquisition August 25, 2015 9:20 AM Stifel Reiterates Buy on Medivation (MDVN) Following Talazoparib Acquisition August 25, 2015 8:45 AM Wedbush Cuts Price Target on BioMarin Pharma (BMRN) Following Announced Sale of Talazoparib to Medivation (MDVN) August 25, 2015 6:55 AM RBC Capital Positive on BioMarin Pharma (BMRN) Following Talazoparib Sale (MDVN)August 24, 2015 10:29 AM Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarinAugust 24, 2015 7:00 AM Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarinAugust 24, 2015 7:00 AM